Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS-GCGRRx- Dose Level 1 · 2 trials · 2 indications
Change from Baseline
Change from Baseline to Week 14
| Arm | Type | Description |
|---|---|---|
| ISIS-GCGRRx - Dose Level 1 | EXPERIMENTAL | ISIS-GCGRRx - Dose Level 1 |
| ISIS-GCGRRx - Dose Level 2 | EXPERIMENTAL | ISIS-GCGRRx - Dose Level 2 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| ISIS-GCGRRx Dose Level 1 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 1 |
| ISIS-GCGRRx Dose Level 2 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 2 |
| Name | Type | Description |
|---|---|---|
| ISIS-GCGRRx- Dose Level 1 | DRUG | once weekly dosing for 26 weeks |
| ISIS-GCGRRx- Dose Level 2 | DRUG | once weekly dosing for 26 weeks |
| Placebo | DRUG | once weekly dosing for 26 weeks |
| ISIS-GCGRRx - Dose Level 1 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
| ISIS-GCGRRx - Dose Level 2 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI ≥ 25.0 kg/m2 * HbA1c ≥ 8.0% and ≤ 10.5% * Type 2 Diabetes Mellitus and on stable dose of Metformin * Agree to conduct home-based (fasted) blood glucose testing as directed Exclusion Criteria: * Clinically significant abnormalities in medica...
Top 20 of 31 competitors
ISIS-GCGRRx-Dose Level 1 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus and Type 2 Diabetes. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ISIS-GCGRRx-Dose Level 1 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ISIS-GCGRRx-Dose Level 1 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The drug is being studied for its potential use in treating Type 2 Diabetes.
ISIS-GCGRRx-Dose Level 1 has been studied in two completed Phase 2 clinical trials. The first trial, NCT01885260, enrolled 77 participants with Type 2 Diabetes Mellitus in the United States and South Africa. The second trial, NCT02583919, enrolled 79 participants with Type 2 Diabetes in the United States.
ISIS-GCGRRx-Dose Level 1 is a specific dose level of the investigational drug ISIS-GCGRRx. The clinical trials NCT01885260 and NCT02583919 evaluated the safety, tolerability, and efficacy of ISIS-GCGRRx, with Dose Level 1 being one of the doses studied.